FMOC-p-氨基-D-Phe(BOC)-OH | 214750-77-3

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: FMOC-p-氨基-D-Phe(BOC)-OH
• 中文别名: FMOC-D-4-BOC-氨基苯丙氨酸；FMOC-D-(BOC-4-氨基)苯丙氨酸；FMOC-4-(BOC-氨基)-D-苯丙氨酸；Fmoc-d-4-氨基苯丙氨酸；N-芴甲氧羰基-4-(叔丁氧羰基氨基)-D-苯丙氨酸
• 英文名称: Fmoc-p-amino(Boc)-D-Phe-OH
• 英文别名: Fmoc-p-amino-DPhe(Boc)-OH；Fmoc-D-4-aminoPhe(Boc)；Fmoc-D-Phe(4-NHBoc)-OH；(2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]propanoic acid
• CAS: 214750-77-3
• 化学式: C₂₉H₃₀N₂O₆
• 分子量: 502.567
• InChiKey: KVUAOWDVYMUKPE-RUZDIDTESA-N

物化性质

• 沸点：
  671.0±55.0 °C(Predicted)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  N-alpha-芴甲氧羰基-N-epsilon-叔丁氧羰基-L-赖氨酸 、 FMOC-p-氨基-D-Phe(BOC)-OH 在 N-甲基吗啉 、 哌啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 以56%的产率得到Bz-Lys(Boc)-D-Phe(4-Boc-NH)-OH
  参考文献：
  名称：

  The spectrum between substrates and inhibitors: Pinpointing the binding mode of dengue protease ligands with modulated basicity and hydrophobicity

  摘要：

  DOI：

  10.1016/j.bmc.2021.116412

文献信息

• New Inhibitors of Bacterial Protein Synthesis from a Combinatorial Library of Macrocycles
  作者：Elizabeth A. Jefferson、Satoshi Arakawa、Lawrence B. Blyn、Alycia Miyaji、Stephen A. Osgood、Raymond Ranken、Lisa M. Risen、Eric E. Swayze

  DOI：10.1021/jm010437x

  日期：2002.8.1

  mixture-based combinatorial library of 14-membered macrocycles was synthesized to target ribosomal RNA and uncover a new class of antibacterial agents. High-throughput screening identified a macrocyclic mixture that inhibited cell-free-coupled transcription/translation in Escherichia coli-derived extracts, with an IC(50) value in the 25-50 microM range. In a follow-up library of 64 single macrocycles, 8 gave

  合成了基于混合物的14元大环化合物组合文库，以靶向核糖体RNA并揭示了一类新型的抗菌剂。高通量筛选确定了一种大环混合物，该混合物可抑制大肠杆菌衍生提取物中无细胞偶联的转录/翻译，其IC（50）值在25-50 microM范围内。在64个单个大环的后续库中，在无细胞蛋白质合成抑制试验中，有8个给出的IC（50）值范围为12至50 microM。在翻译抑制试验中筛选了一些大环化合物，IC（50）值通常与未偶联的转录/翻译试验中获得的值平行。在初步的结构-活性关系研究中还制备了其他类似物，和更有效的大环化合物被确定具有低微摩尔活性（IC（50）值= 2-3 microM）。这些大环中的一些显示出对脂多糖突变型大肠杆菌细菌细胞的抗菌活性（IC（50）值= 12-50 microM）。
• Compounds Modifying Apoptosis
  申请人：Thastrup Ole

  公开号：US20080194537A1

  公开（公告）日：2008-08-14

  The present invention relates to compounds capable of inhibiting binding of the Smac protein to Inhibitors of apoptosis (IAPs). Such compounds are preferably capable of inhibiting IAP and thus may promote apoptosis or sensitize cells for apoptosis. The compounds may be used in the treatment of proliferative diseases, such as cancer.

  本发明涉及一种能够抑制Smac蛋白与凋亡抑制剂（IAPs）结合的化合物。这些化合物最好能够抑制IAP，从而可能促进细胞凋亡或增加细胞对凋亡的敏感性。这些化合物可用于治疗增生性疾病，如癌症。
• [EN] TARGETED DRUG-FORMALDEHYDE CONJUGATES AND METHODS OF MAKING AND USING THE SAME<br/>[FR] CONJUGUES CIBLES MEDICAMENT-FORMALDEHYDE ET PROCEDES DE FABRICATION ASSOCIES
  申请人：UNIV COLORADO

  公开号：WO2005034856A3

  公开（公告）日：2005-08-11
• Melanocortin Tetrapeptide Ac-His-DPhe-Arg-Trp-NH₂ Modified at the Para Position of the Benzyl Side Chain (DPhe): Importance for Mouse Melanocortin-3 Receptor Agonist versus Antagonist Activity
  作者：Bettina Proneth、Irina D. Pogozheva、Federico P. Portillo、Henry I. Mosberg、Carrie Haskell-Luevano

  DOI：10.1021/jm800291b

  日期：2008.9.25

  The melanocortin-3 and -4 receptors (MC3R, MC4R) have been implicated in energy homeostasis and obesity. Whereas the physiological role of the MC4R is extensively studied, little is known about the MC3R. One caveat is the limited availability of ligands that are selective for the MC3R. Previous studies identified Ac-His-DPhe(p-I)-Arg-Trp-NH2, which possessed partial agonist/antagonist pharmacology at the mMC3R while retaining full nanomolar agonist pharrnacology at the mMC4R. These data allowed for the hypothesis that the DPhe position in melanocortin tetrapeptides can be used to examine ligand side-chain determinants important for differentiation of mMC3R agonist versus antagonist activity. A series of 15 DPhe(7) modified Ac-His-DPhe(7)-Arg-Trp-NH2 tetrapeptides has been synthesized and pharmacologically characterized. Most notable results include the identification of modifications that resulted in potent antagonists/partial agonists at the mMC3R and full, potent agonists at the mMC4R. These SAR studies provide experimental evidence that the molecular mechanism of antagonism at the mMC3R differentiates this subtype from the mMC4R.
• EPOXIDE INHIBITORS OF CYSTEINE PROTEASES
  申请人：Bogyo Matthew S.

  公开号：US20080176841A1

  公开（公告）日：2008-07-24

  Provided herein are novel epoxide inhibitors of cysteine proteases, compositions comprising the epoxide inhibitors, and packaged pharmaceuticals. Also provided are methods of inhibiting a papain-family cysteine protease and methods of treating or preventing a disease by administering a composition containing an epoxide inhibitor of the invention. The compositions may be administered in combination with another therapeutic agent.